BOSTON, MA, UNITED STATES, April 24, 2025 /EINPresswire / -- Affini-T Therapeutics to present data from pipeline programs targeting the cancer driver mutations KRAS G12V and TP53 R175H.

Their specific target was a peptide containing the R175H mutation of p53 (the 175th amino acid of p53 is mutated from arginine to histidine), displayed on the HLA-A2 allele (gene variation).